$12.20
4.69% day before yesterday
Nasdaq, May 23, 10:00 pm CET
ISIN
IL0011280240
Symbol
ARCT
Sector
Industry

Arcturus Therapeutics Ltd Target price 2025 - Analyst rating & recommendation

Arcturus Therapeutics Ltd Classifications & Recommendation:

Buy
100%

Arcturus Therapeutics Ltd Price Target

Target Price $65.56
Price $12.20
Potential
Number of Estimates 9
9 Analysts have issued a price target Arcturus Therapeutics Ltd 2026 . The average Arcturus Therapeutics Ltd target price is $65.56. This is higher than the current stock price. The highest price target is
$140.00 1,047.54%
register free of charge
, the lowest is .
A rating was issued by 11 analysts: 11 Analysts recommend Arcturus Therapeutics Ltd to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Arcturus Therapeutics Ltd stock has an average upside potential 2026 of . Most analysts recommend the Arcturus Therapeutics Ltd stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 152.31 92.55
8.69% 39.24%
EBITDA Margin -60.49% -138.82%
34.08% 129.50%
Net Margin -53.14% -86.74%
198.15% 63.22%

11 Analysts have issued a sales forecast Arcturus Therapeutics Ltd 2025 . The average Arcturus Therapeutics Ltd sales estimate is

$92.5m
Unlock
. This is
35.59% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$140m 2.35%
Unlock
, the lowest is
$29.4m 79.55%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $152m 8.69%
2025
$92.5m 39.24%
Unlock
2026
$104m 12.66%
Unlock
2027
$235m 125.74%
Unlock
2028
$527m 124.10%
Unlock
2029
$792m 50.24%
Unlock

2 Analysts have issued an Arcturus Therapeutics Ltd EBITDA forecast 2025. The average Arcturus Therapeutics Ltd EBITDA estimate is

$-128m
Unlock
. This is
63.36% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-102m 29.83%
Unlock
, the lowest is
$-155m 96.90%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-92.1m 22.43%
2025
$-128m 39.44%
Unlock
2026
$-140m 9.15%
Unlock
2027
$-85.7m 38.88%
Unlock

EBITDA Margin

2024 -60.49% 34.08%
2025
-138.82% 129.50%
Unlock
2026
-134.50% 3.11%
Unlock
2027
-36.42% 72.92%
Unlock

3 Arcturus Therapeutics Ltd Analysts have issued a net profit forecast 2025. The average Arcturus Therapeutics Ltd net profit estimate is

$-80.3m
Unlock
. This is
17.71% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-65.9m 3.37%
Unlock
, the lowest is
$-90.9m 33.21%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-80.9m 172.25%
2025
$-80.3m 0.82%
Unlock
2026
$-78.9m 1.69%
Unlock
2027
$-85.7m 8.54%
Unlock

Net Margin

2024 -53.14% 198.15%
2025
-86.74% 63.22%
Unlock
2026
-75.69% 12.74%
Unlock
2027
-36.40% 51.91%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -3.00 -2.96
167.86% 1.33%
P/E negative
EV/Sales 1.39

3 Analysts have issued a Arcturus Therapeutics Ltd forecast for earnings per share. The average Arcturus Therapeutics Ltd EPS is

$-2.96
Unlock
. This is
17.46% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-2.43 3.57%
Unlock
, the lowest is
$-3.35 32.94%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.00 167.86%
2025
$-2.96 1.33%
Unlock
2026
$-2.91 1.69%
Unlock
2027
$-3.16 8.59%
Unlock

P/E ratio

Current -4.84 35.14%
2025
-4.12 14.90%
Unlock
2026
-4.19 1.70%
Unlock
2027
-3.86 7.88%
Unlock

Based on analysts' sales estimates for 2025, the Arcturus Therapeutics Ltd stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.90 78.21%
2025
1.39 54.78%
Unlock
2026
1.24 11.23%
Unlock
2027
0.55 55.70%
Unlock
2028
0.24 55.39%
Unlock
2029
0.16 33.43%
Unlock

P/S ratio

Current 2.30 64.26%
2025
3.58 55.25%
Unlock
2026
3.17 11.24%
Unlock
2027
1.41 55.70%
Unlock
2028
0.63 55.38%
Unlock
2029
0.42 33.44%
Unlock

Current Arcturus Therapeutics Ltd Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Wells Fargo
Locked
Locked
Locked May 14 2025
Canaccord Genuity
Locked
Locked
Locked May 13 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 10 2025
Canaccord Genuity
Locked
Locked
Locked Mar 10 2025
Cantor Fitzgerald
Locked
Locked
Locked Mar 07 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 07 2025
Wells Fargo
Locked
Locked
Locked Mar 07 2025
Analyst Rating Date
Locked
Wells Fargo:
Locked
Locked
May 14 2025
Locked
Canaccord Genuity:
Locked
Locked
May 13 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 10 2025
Locked
Canaccord Genuity:
Locked
Locked
Mar 10 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Mar 07 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 07 2025
Locked
Wells Fargo:
Locked
Locked
Mar 07 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today